{"id":"W3169033905","doi":"10.1200/jco.2013.31.4_suppl.314","title":"A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma (HCC).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Axitinib; Medicine; Sorafenib; Pazopanib; Internal medicine; Clinical endpoint; Temsirolimus; Hepatocellular carcinoma; Oncology; Progressive disease; Gastroenterology; Interim analysis; Sunitinib; Surgery; Clinical trial; Renal cell carcinoma; Chemotherapy; Discovery and development of mTOR inhibitors","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001660724,0.001297075,0.001518038,0.0004326208,0.0003419429,0.0007098063,0.0006492563,0.001104793,0.007173675],"category_scores_gemma":[0.0007833488,0.0004280964,0.0009620136,0.0003432427,0.0006985182,0.0006839402,0.0003522295,0.002473636,0.001503529],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007022038,"about_ca_system_score_gemma":0.001428764,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007266094,"about_ca_topic_score_gemma":0.001948859,"domain_scores_codex":[0.9996483,0.0001712734,0.00001687794,0.00004580351,0.00002865266,0.00008911164],"domain_scores_gemma":[0.9993581,0.00009378792,0.00009962624,0.00005772235,0.00003404641,0.0003567484],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8731818,0.0475838,0.00397656,0.0006967539,0.0005469702,0.0003044409,0.0001551928,0.001131376,0.017295,0.0002031568,0.00381644,0.0511086],"study_design_scores_gemma":[0.7643454,0.2268969,0.00425837,0.00001947145,0.0001612773,0.0002136534,0.00002426009,0.0008108279,0.001627857,0.000111283,0.001519579,0.00001100717],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9885283,0.001485825,0.0006754899,0.0005475676,0.0002403612,0.004241842,0.001386602,0.0001241763,0.002769901],"genre_scores_gemma":[0.9808406,0.001322604,0.001740853,0.0008193096,0.0002303144,0.004713104,0.004548486,0.00003026289,0.0057545],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007173675,"threshold_uncertainty_score":0.02399838,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1712810867158238,"score_gpt":0.4200956653860514,"score_spread":0.2488145786702276,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}